Results 231 to 240 of about 88,666 (249)
Some of the next articles are maybe not open access.
Cancer, 1978
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +3 more sources
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +3 more sources
Current Opinion in Oncology, 2003
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +2 more sources
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +2 more sources
Biotherapy of chronic myelogenous leukemia
Annals of Hematology, 1995The aim of this review is to summarize the current knowledge on the clinical results of biotherapy of chronic myelogenous leukemia (CML) and potential mechanisms of the antitumor action of interferon alpha. IFN alpha treatment induces hematologic and cytogenetic remissions in patients with chronic phase CML.
Christoph Huber +3 more
openaire +3 more sources
MYELOGENOUS AND LYMPHATIC LEUKEMIA
AJN, American Journal of Nursing, 1919I have been asked to tell something about my work with blood diseases. I have chosen as my subject, "Leukemia," as I feel that as nurses we come in contact with this terrible disease less often than any other, and have, therefore, considered it a rare condition. Review of the literature.-It has been stated that in 1845, Huges Bennett recorded a case of
openaire +2 more sources
Smouldering Acute Myelogenous Leukemia
Acta Medica Scandinavica, 1978ABSTRACT. Among 195 patients with variants of acute myelogenous leukemia (AML), a minimum of 11 met our criteria of smouldering AML: patients with less than 30% of blast cells plus promyelocytes in the bone marrow at the time of diagnosis who were observed without specific antileukemic therapy for a period of at least 6 months without entering a ...
Per Stavem, Stein A. Evensen
openaire +3 more sources
The Patient with “Myelogenous Osteopathy”
2016Neumann and Bizzozero published almost simultaneously in 1868 that the bone marrow and the bone are closely interrelated organs. The term “haematic osteodysplasia” was first introduced by Gaensslen in 1938 to describe the effects on the skull caused by congenital haemolytic anaemias, i.e.
Christoph Bartl, Reiner Bartl
openaire +2 more sources
Current Cancer Therapy Reviews, 2009
Chronic myelogenous leukemia, BCR-ABL1+ (CML), is a myeloproliferative neoplasm defined by the presence of the BCR-ABL fusion gene produced by the t(9;22)(q32;q11) cytogenetic abnormality. CML manifests clinically as leukocytosis with circulating immature granulocytic precursors and splenomegaly.
openaire +2 more sources
Chronic myelogenous leukemia, BCR-ABL1+ (CML), is a myeloproliferative neoplasm defined by the presence of the BCR-ABL fusion gene produced by the t(9;22)(q32;q11) cytogenetic abnormality. CML manifests clinically as leukocytosis with circulating immature granulocytic precursors and splenomegaly.
openaire +2 more sources
Progress in Acute Myelogenous Leukemia
Annals of Internal Medicine, 1984There has been substantial recent progress in the treatment of acute myelogenous leukemia (AML). Intensive induction chemotherapy with cytosine arabinoside and daunorubicin with or without 6-thioguanine will induce remission in over 70% of patients, with median remission of 1-2 years in most series.
openaire +4 more sources
2014
The impact of age as a poor prognostic factor in chronic myeloid leukemia (CML) has been well described. In the interferon era, elderly patients diagnosed with CML in chronic phase had shorter survival compared to younger patients. With the advent of targeted therapy with imatinib, studies described consistently improved responses in elderly late ...
Andreas Hochhaus, Susanne Saussele
openaire +2 more sources
The impact of age as a poor prognostic factor in chronic myeloid leukemia (CML) has been well described. In the interferon era, elderly patients diagnosed with CML in chronic phase had shorter survival compared to younger patients. With the advent of targeted therapy with imatinib, studies described consistently improved responses in elderly late ...
Andreas Hochhaus, Susanne Saussele
openaire +2 more sources
2016
After a peak during the first 2 years of life, the incidence of acute myelogenous leukemia (AML) is low (five per million 5- to 9-year-olds per year in the United States) until after 9 years of age, when it slowly increases during adolescence and adulthood (to nine per million per year among 15- to 19-year-olds in the United States).
Richard F. Schlenk +2 more
openaire +2 more sources
After a peak during the first 2 years of life, the incidence of acute myelogenous leukemia (AML) is low (five per million 5- to 9-year-olds per year in the United States) until after 9 years of age, when it slowly increases during adolescence and adulthood (to nine per million per year among 15- to 19-year-olds in the United States).
Richard F. Schlenk +2 more
openaire +2 more sources